
Amomum villosum Lour. has been traditionally valued in various cultures for its health benefits. Here, we show that the neuroprotective effects of the essential oils extracted from the fruit of Amomum villosum Lour. (AVEO) and elucidate its underlying mechanisms in lipopolysaccharide (LPS)-induced neuroinflammation. The main compounds of AVEO can cross the blood-brain barrier and significantly improve cognitive and behavioral dysfunction in LPS-induced mice, leading to a 50% enhancement in Morris water maze performance, a 60% and 80% reduction in immobility time in the tail suspension test and forced swimming test, respectively. Moreover, AVEO mitigates neuron loss and suppresses the expression of pro-inflammatory mediators, including TNF-alpha, IL-1 beta, and IL-6, while upregulating the anti-inflammatory cytokine IL-10 in brain tissue. RNA-seq and metabonomics analyses reveal that AVEO modulates multiple inflammation-related pathways and restore metabolic homeostasis in brain tissue. Remarkably, AVEO attenuates hyperactivation of the PI3K-Akt and MAPK signaling pathways in LPS-induced microglia and improves neuronal damage in LPS-induced microglia-neuron co-culture system. Altogether, our findings suggest that AVEO alleviates neural dysfunction by modulating PI3K-Akt and MAPK signaling cascades and promoting metabolic reprogramming upon neuroinflammation, thereby revealing the therapeutic potential of AVEO in several neurological disorders.
Type 2 diabetes mellitus (T2DM) is frequently accompanied by chronic ethanol (ET) consumption, which worsens metabolic dysregulation and organ damage. Cinnamic acid (CA), a natural compound with anti-diabetic and hepatoprotective effects, shows therapeutic potential, but its role in mitigating ET-exacerbated hepatocyte injury in diabetes remains unclear. This study thus investigated whether CA protects against ET-induced hepatocyte pyroptosis under diabetic conditions and explored the underlying mechanisms. In vitro, HepG2 cells cultured under high-glucose (HG) conditions were exposed to ET to simulate a diabetic state with concomitant alcohol intake. Pyroptosis was evaluated by morphological examination and annexin V/PI staining. The involvement of the NACHT, LRR and PYD domains-containing protein 3 (NLRP3)/gasdermin D (GSDMD) pathway and AMP-activated protein kinase (AMPK) activation was assessed via immunoblotting, reactive oxygen species (ROS) detection, and molecular docking. In vivo, a T2DM mouse model was established using a high-fat diet combined with streptozotocin injection, followed by ET exposure and CA treatment. Metabolic parameters, histopathological changes, and hepatic signaling pathways were analyzed. Our results showed that ET exposure significantly increased pyroptotic body formation, ROS production, and NLRP3/GSDMD pathway activation in HG-treated HepG2 cells-all of which were reversed by CA in a concentration-dependent manner. Mechanistically, CA directly bound to and activated AMPK, and the protective effects were abolished by the AMPK inhibitor Compound C. In T2DM mice, ET exposure aggravated insulin resistance, dyslipidemia, hepatic steatosis, and histopathological abnormalities, whereas CA intervention ameliorated these adverse effects and modulated the AMPK-NLRP3/GSDMD signaling axis in liver tissue. Collectively, these findings demonstrate that CA alleviates ET-exacerbated hepatocyte pyroptosis under diabetic conditions by activating AMPK and subsequently inhibiting the NLRP3/GSDMD signaling cascade. This study provides novel insights into the therapeutic potential of CA in T2DM complicated by alcoholic hepatocellular injury.
Diabetic osteoporosis (DOP) is characterized by chronic low-grade inflammation and impaired bone formation. Pinoresinol diglucoside (PDG), a bioactive compound derived from Eucommia ulmoides Oliv., has shown therapeutic potential in metabolic bone disorders; however, its direct molecular targets and integrated mechanisms remain unclear. This study aimed to elucidate the metabolic basis and molecular targets through which PDG protects against high glucose (HG)-induced osteoblast dysfunction and diabetic bone loss. Osteogenic effects of PDG were evaluated in HG-exposed osteoblasts, with untargeted metabolomics, qPCR, Western blotting, molecular docking, SPR, and siRNA-mediated knockdown applied to identify altered pathways and validate target necessity. In vivo, PDG was administered to db/db mice with DOP for 8 weeks, followed by micro-CT, bone metabolism factors, histomorphometry, and immunofluorescence analyses. Metabolomic profiling identified arachidonic acid metabolism as the central pathway dysregulated in HG conditions and rescued by PDG. PDG directly bound and inhibited both p65 (NF-kappa B) and GSK3 beta. Mechanistically, p65 knockdown abolished the anti-inflammatory effect of PDG without affecting osteogenesis, whereas GSK3 beta knockdown abrogated beta-catenin activation and osteogenic differentiation without affecting anti-inflammatory responses, indicating that they function as parallel and independent branches. Simultaneous knockdown of both completely blocked the functional recovery of osteoblast differentiation. In DOP mice, PDG significantly improved trabecular microarchitecture and bone metabolic homeostasis, reduced local PGE2 levels with an effect directly targeting bone, inhibited p65 nuclear translocation, and restored beta-catenin nuclear localization. PDG ameliorates DOP by dual targeting p65 and GSK3 beta, coordinately inhibiting NF-kappa B-mediated inflammation and activating the beta-catenin osteogenic program, highlighting its therapeutic potential for DOP.
Obesity is a chronic, recurrent, and progressive disease caused by energy imbalance. N6-methyladenosine (m6A) modification regulates fat thermogenesis, potentially counteracting obesity. Mogroside V (MV) is a triterpene glycoside extracted from Siraitia grosvenorii and has shown beneficial effects in models of obesity. However, its underlying mechanism remains unknown. The objective of this study is to investigate the effects of MV on adipose thermogenesis and explore the mechanism of m6A modifications in mediating these effects. Mitochondrial respiration analysis, histological and molecular biological methods were used to investigate the thermogenesis in differentiated C3H10T1/2 brown adipocytes and adipose tissue in high-fat diet (HFD)-fed mouse models, respectively. Stable cell models with overexpression or knockdown of fat mass and obesity-associated protein (FTO) were generated to investigate the effects of FTO on m6A modification and thermogenesis in brown adipocytes. Methylated RNA immunoprecipitation-quantitative-PCR (MeRIP-qPCR) and RIP-qPCR analysis were used to reveal the potential downstream molecular targets of FTO. MV improved HFD-induced obesity and metabolic dysfunction in mice. MV also increased uncoupling protein 1 (UCP1) expression in brown adipose tissue and enhanced mitochondrial respiration and expression of peroxisome proliferator activated receptor gamma coactivator 1 alpha (PGC1 alpha) and UCP1 in differentiated C3H10T1/2 cells. Further analysis of the relevant molecular mechanisms showed that MV suppressed FTO expression, thereby increasing m6A modification of LETM1 domain-containing protein 1 (Letmd1) mRNA. The m6A-modified Letmd1 transcript was recognized by the m6A reader YTH domain-containing protein 2 (YTHDC2), thereby increasing the stability of Letmd1 mRNA. The increased Letmd1 mRNA levels were correlated with increased LETMD1 protein abundance, which subsequently enhanced the expression of PGC1 alpha and UCP1, ultimately promoting brown adipocyte thermogenesis. MV promoted brown adipocyte thermogenesis through the FTO-m6A-LETMD1-UCP1 axis, suggesting a potential therapeutic strategy for obesity.
This study investigates the hepatoprotective effects and underlying molecular mechanisms of Oxypaeoniflorin (Opae) against alcohol-associated liver disease (ALD). An in vivo ALD mouse model was established by chronic feeding of Lieber-DeCarli EtOH-containing liquid diets combined with TEAD4 silencing is utilized to explore the protective function of Opae. Opae treatment effectively ameliorated alcoholic liver damage, accompanied by significant downregulation of hepatic P-YAP1, TEAD1, and TEAD4 levels, as well as reduced expression of the pyroptosis-associated proteins NLRP3 and IL-1 beta. RNA sequencing analysis further identified the NOD-like receptor/mitophagy/Hippo signaling axis as the core regulatory network mediating Opae-induced hepatoprotection. Mechanistically, dual-luciferase reporter assays in AML-12 hepatocytes validated the direct binding of TEAD4 to the NLRP3 promoter. Both siRNA-mediated TEAD4 silencing in AML-12 cells and shRNA-mediated hepatic TEAD4 silencing in mice markedly suppressed NLRP3 expression and alleviated liver inflammatory responses. Notably, TEAD4 depletion abrogated EtOH-induced NLRP3 activation, confirming the essential transcriptional regulatory role of TEAD4 on NLRP3. In addition to the intrinsic regulatory effect on hepatocytes, Opae inhibits pyroptosis in LPS-stimulated mouse peritoneal macrophages (MPMs). Conditioned medium collected from Opae-treated MPMs significantly attenuated EtOH-induced inflammatory injury in primary mouse hepatocytes. Collectively, Opae exerts prominent hepatoprotective effects in ALD by suppressing TEAD4-NLRP3-mediated pyroptosis.